sars-cov-2 neutralizing antibodies (nab)  (Cayman Chemical)

Journal: Frontiers in Immunology

Article Title: Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity

doi: 10.3389/fimmu.2024.1401728

Figure Lengend Snippet: Anti-HCoV spike-binding antibody titers at baseline in sub-study participants who received two doses of AZD1222, by post-treatment SARS-CoV-2 nucleocapsid serostatus. Post-treatment SARS-CoV-2 seropositivity was defined by the presence of an above threshold (>9787 AU mL-1) response to SARS-CoV-2 nucleocapsid antibodies occurring ≥15 days after receiving a second dose of AZD1222. The bottom and top edges of the box indicate the first and third quartiles (the difference is the IQR), the line inside the box is the median, and the marker inside the box is the geometric mean. Any points more than 1.5 x IQR from the box were considered outliers and are not displayed. The whiskers that extend from the box indicate the minimum and maximum after removing the outliers. Boxplots are created using log transformed values. Titer values measured as below LLoQ are imputed to half the LLoQ. Titer values measured as above ULoQ are imputed at the ULoQ value. HCoV, human coronavirus, IQR, interquartile range, LLoQ, lower limit of quantification, ULoQ, upper limit of quantification, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Article Snippet: SARS-CoV-2 pseudovirus neutralizing antibody (nAb) levels were determined via a validated lentivirus-based ancestral (Wuhan D614) assay by Labcorp-Monogram Biosciences (South San Francisco, CA, USA) ( , , ).

Techniques: Binding Assay, Marker, Transformation Assay

Journal: Frontiers in Immunology

Article Title: Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity

doi: 10.3389/fimmu.2024.1401728

Figure Lengend Snippet: Time to SARS-CoV-2 nucleocapsid seroconversion in post-treatment SARS-CoV-2 nucleocapsid seropositive sub-study participants who received two doses of AZD1222, by HCoV titer quartile at baseline for (A) HCoV-229E (B) HCoV-HKU1 (C) HCoV-NL63 (D) HCoV-OC43. Participants who received two doses of AZD1222 were sorted by HCoV titer at baseline with quartile one denoting participants with the lowest baseline titers and quartile four the highest baseline anti-HCoV spike-binding antibody titers. Post-treatment SARS-CoV-2 seropositivity was defined by the presence of an above threshold (>9787 AU mL -1 ) response to SARS-CoV-2 nucleocapsid antibodies occurring ≥15 days after receiving a second dose of AZD1222. The time to first post-treatment response has been calculated as follows: In days, the date of post-treatment response – (date of second dose of study intervention + 14) +1. For censored participants, the censoring time is from date of second dose of study intervention + 14, to last observed time during the analysis period/non-study COVID-19 vaccine administration. The bottom and top edges of the box indicate the first and third quartiles (the difference is the IQR), the line inside the box is the median, and the marker inside the box is the mean. Any points more than 1.5 x IQR from the box are considered outliers and are not displayed. The whiskers that extend from the box indicate the minimum and maximum after removing the outliers. Titer values measured as below LLoQ are imputed to half the LLoQ. Titer values measured as above ULoQ are imputed at the ULoQ value. HCoV, human coronavirus, IQR, interquartile range, LLoQ, lower limit of quantification, ULoQ, upper limit of quantification, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Article Snippet: SARS-CoV-2 pseudovirus neutralizing antibody (nAb) levels were determined via a validated lentivirus-based ancestral (Wuhan D614) assay by Labcorp-Monogram Biosciences (South San Francisco, CA, USA) ( , , ).

Techniques: Binding Assay, Marker

Journal: ACS Applied Materials & Interfaces

Article Title: Rapid, Sensitive, Label-Free Electrical Detection of SARS-CoV-2 in Nasal Swab Samples

doi: 10.1021/acsami.3c00331

Figure Lengend Snippet: Schematic images of (a) infection process of SARS-CoV-2 mediated by the interaction between the viral SP and ACE-2 on the cell membrane; NAbs that are responsible for defending cells from pathogens are made by B-cells in the bone marrow. (b) Schematic images of label-free detection of SARS-CoV-2 using the RFGFET with either NAb or ACE-2 probes on rGO sensing layers of the RFG; a SP probe on rGO was also used for detection of NAbs. (c) V th and G m levels of the RFGFET changed by different surface conditions on the RFG; all RFGFETs were measured in the 1× PBS buffer solution using the same MOFEST and Ag/AgCl reference electrode.

Article Snippet: The fabricated rGO RFG modules were fully immersed in a 10 mg/mL 1-pyrenebutyric acid N -hydroxysuccinimide ester (PBASE) (Santa Cruz Biotechnology, 114932-60-4) diluted in dimethylformamide (DMF) for 2 h. After washing the rGO surfaces by DMF, 250 μg/mL SARS-CoV-2 NAb (Sino Biological, 40592-MM57) was incubated on the rGO surface for at least 2 h. Sequentially, a 10 mg/mL BSA solution dissolved in 1× PBS was added for at least 2 h. The SARS-CoV-2 SP (Sino Biological, 40592-V08B) was diluted in 0.05 × PBS to concentrations of 34 fg/mL to 3.4 μg/mL for testing media.

Techniques: Infection

Journal: ACS Applied Materials & Interfaces

Article Title: Rapid, Sensitive, Label-Free Electrical Detection of SARS-CoV-2 in Nasal Swab Samples

doi: 10.1021/acsami.3c00331

Figure Lengend Snippet: (a) ΔV th of rGO with NAb or SP probes vs concentrations of SP or NAb in PBS, respectively. ELISA signals (NAb probes on rGO substrates vs SP) were compared. (b) ΔV th and CV value of rGO with ACE-2 probes vs concentrations of SP in PBS. (c) ΔV th of rGO with NAb probe or pristine rGO vs concentrations of pseudo-SARS-CoV-2 in PBS; ELISA measurements performed on a standard well plate and rGO substrates were compared. (d) ΔV th of pristine rGO vs concentrations of SP, BSA, and NAb, respectively, and ΔV th of BSA-blocked rGO vs SP. (e) ΔV th of rGO with NAb probes vs concentrations of SP in artificial saliva mixture. (f) ΔV th of rGO with NAb or ACE-2 probes vs concentrations of pseudo-SARS-CoV-2 in artificial saliva mixture and ΔV th of BSA-blocked rGO or pristine rGO vs concentrations of pseudo-SARS-CoV-2 in artificial saliva mixture.

Article Snippet: The fabricated rGO RFG modules were fully immersed in a 10 mg/mL 1-pyrenebutyric acid N -hydroxysuccinimide ester (PBASE) (Santa Cruz Biotechnology, 114932-60-4) diluted in dimethylformamide (DMF) for 2 h. After washing the rGO surfaces by DMF, 250 μg/mL SARS-CoV-2 NAb (Sino Biological, 40592-MM57) was incubated on the rGO surface for at least 2 h. Sequentially, a 10 mg/mL BSA solution dissolved in 1× PBS was added for at least 2 h. The SARS-CoV-2 SP (Sino Biological, 40592-V08B) was diluted in 0.05 × PBS to concentrations of 34 fg/mL to 3.4 μg/mL for testing media.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Journal of Clinical Biochemistry and Nutrition

Article Title: Serum titer of neutralizing antibodies after COVID-19 vaccination in Japanese patients with inflammatory bowel disease

doi: 10.3164/jcbn.22-60

Figure Lengend Snippet: Boxplot of anti-SARS-CoV-2 neutralizing antibodies after vaccination and positive rate of anti-SARS-CoV-2 neutralizing antibody. Box and whisker plots are shown where the box contains 50% of the data, the bar represents the median value, and the upper and lower whiskers represent scores outside the middle 50%. (A) Boxplot of anti-SARS-CoV-2 neutralizing antibodies after vaccination of UC, CD, and control groups. Antibody titer not significantly different by multiple comparison test. (B) Positive rate of anti-SARS-CoV-2 neutralizing antibody of UC, CD, and control groups. 10 AU/ml of neutralizing antibody was used as cut off. * p <0.05 compared to control. (C) Boxplot of anti-SARS-CoV-2 neutralizing antibodies after vaccination according to immunosuppressive therapy. Antibody titer is not significantly different by multiple comparison test. (D) Positive rate of anti-SARS-CoV-2 neutralizing antibody according to immunosuppressive therapy. (E) Boxplot of anti-SARS-CoV-2 neutralizing antibodies after vaccination according to number of immunosuppressive therapies. (F) Positive rate of anti-SARS-CoV-2 neutralizing antibodies according to number of immunosuppressive therapies.

Article Snippet: Anti-SARS-CoV-2 neutralizing antibodies (NAbs) and SARS-CoV-2 IgG were performed on an iFlash3000 automated magnetic CLIA (MCLIA) analyzer from Shenzhen YHLO Biotech Co., Ltd. (Shenzhen, China).

Techniques: Whisker Assay

Journal: Journal of Clinical Biochemistry and Nutrition

Article Title: Serum titer of neutralizing antibodies after COVID-19 vaccination in Japanese patients with inflammatory bowel disease

doi: 10.3164/jcbn.22-60

Figure Lengend Snippet: Anti-SARS-CoV-2 neutralizing antibody concentration over time. (A) Anti-SARS-CoV-2 neutralizing antibody concentration over time of UC, CD, and control groups. When we analysed CoV-2 Nab by patients’ category (as fixed factors) and days since vaccinated using ANCOVA, the analysis revealed no interaction between patients’ category and days since vaccination ( p = 0.725). (B) Anti-SARS-CoV-2 neutralizing antibody concentration over time according to immunosuppressive therapy. When we analysed CoV-2 Nab by Immunosuppressive therapy and days since vaccinated using ANCOVA, the analysis revealed no interaction between Immunosuppressive therapy and days since vaccination ( p = 0.313). (C) Anti-SARS-CoV-2 neutralizing antibody concentration over time according to number of immunosuppressive therapies. When we analysed CoV-2 Nab by Immunosuppressive therapy and days since vaccinated using ANCOVA, the analysis revealed no interaction between Immunosuppressive therapy and days since vaccination ( p = 0.538).

Article Snippet: Anti-SARS-CoV-2 neutralizing antibodies (NAbs) and SARS-CoV-2 IgG were performed on an iFlash3000 automated magnetic CLIA (MCLIA) analyzer from Shenzhen YHLO Biotech Co., Ltd. (Shenzhen, China).

Techniques: Concentration Assay